KNUST gets Green Light to Commence Clinical Trials for Potential Treatment for Coronavirus

KNUST gets Green Light to Commence Clinical Trials for Potential Treatment for Coronavirus

The School of Public Health at the Kwame Nkrumah University of Science and Technology in the Ashanti regional capital, Kumasi has been given the approval to commence clinical trials of a potential treatment for COVID-19.

The approval was granted by the Food and Drugs Authority (FDA) and the National Medicine Regulatory Agency (NMRA) for the herbs Cryptolepis sanguinolenta, known locally as Nibima, Kadze, and Gangamau respectively.

The FDA in a press release on Monday explained that the approval followed the “results from laboratory studies conducted by the KNUST research team which points in the direction of possible clinical benefits”.

“The Food and Drugs Authority (FDA), the National Medicine Regulatory Agency (NMRA) in Ghana, has approved a herbal medicine, Cryptolepis sanguinolenta, locally known as Nibima for clinical trials in January 2021.”

“In search for a treatment for the ongoing COVID-19 pandemic researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology (KNUST), submitted a clinical trial application in September 2020 to assess the safety and efficacy of Cryptolepis sanguinolenta as a potential treatment for Covid-19. This follows results from laboratory studies conducted by the KNUST research team which points in the direction of possible clinical benefits” the release added.

“The Food and Drugs Authority (FDA), the National Medicine Regulatory Agency (NMRA) in Ghana, has approved a herbal medicine, Cryptolepis sanguinolenta, locally known as Nibima for clinical trials in January 2021.”

“In search for a treatment for the ongoing COVID-19 pandemic researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology (KNUST), submitted a clinical trial application in September 2020 to assess the safety and efficacy of Cryptolepis sanguinolenta as a potential treatment for Covid-19. This follows results from laboratory studies conducted by the KNUST research team which points in the direction of possible clinical benefits.”